Skip to main content Skip to main navigation menu Skip to site footer

Effects of misoprostol as a drug to induce abortion in the second trimester: a forensic case report

  • Arfi Syamsun ,
  • Jaury Sutjianto ,
  • Elita Rahma ,
  • Rina Masadah ,
  • Husni Cangara ,
  • Berti Julian Nelwan ,


Abstract

Link of Video Abstract: https://youtu.be/rMasD6pMero

 

Introduction: Induced abortion with misoprostol in the second trimester can be harmful to both mother and fetus, especially when the abortion is self-administered with telemedicine. Considering the effects that might occur in misoprostol usage to induce abortion, we ought to present our experience through this article regarding the effect of misoprostol as a drug to induce abortion in the second trimester.

Case Description: In the first case, a 30-year-old woman engaged in a self-induced abortion at her residence subsequent to consulting with medical personnel at a local community health centre, where she received oral and vaginal administration of misoprostol. Unfortunately, complications arose as the mother experienced post-abortion bleeding, which necessitated a curative procedure. Tragically, the fetus perished in utero due to asphyxia. In the second case, a 20-year-old woman opted to undergo a self-induced abortion at home following consultation and the acquisition of misoprostol from an online source. In cases where fetuses experience asphyxia within the womb, they are unable to exit the uterus spontaneously. Consequently, the mother experienced post-abortion bleeding as an aftermath of the procedure.

Conclusions: Misoprostol-induced abortion in the second trimester causes maternal bleeding and intrauterine fetal mortality. Medical staff should handle abortions professionally, considering into account both the patient's health and the legal considerations.

Keywords: Induced abortion misoprostol telemedicine second trimester

References

  1. Sedgh G, Bankole A, Oye-Adeniran B, Adewole IF, Singh S, Hussain R. Unwanted pregnancy and associated factors among Nigerian women. Int Fam Plan Perspect. 2006;32(4):175–84. DOI: https://doi.org/10.1363/3217506.
  2. Sedgh G, Henshaw S, Singh S, Åhman E, Shah IH. Induced abortion: estimated rates and trends worldwide. Lancet. 2007;370(9595):1338–45. DOI: https://doi.org/10.1016/s0140-6736(07)61575-x.
  3. Shaikh Z, Abbassi RM, Rizwan N, Abbasi S. Morbidity and mortality due to unsafe abortion in Pakistan. Int J Gynecol Obstet. 2010;110(1):47–9. DOI: http://dx.doi.org/10.1016/j.ijgo.2010.01.028
  4. Walters KM, Simon RA, Woessner KM, Wineinger NE, White AA. Effect of misoprostol on patients with aspirin-exacerbated respiratory disease undergoing aspirin challenge and desensitization. Ann Allergy, Asthma Immunol. 2017;119(1):71–6. DOI: http://dx.doi.org/10.1016/j.anai.2017.05.003
  5. Kurniawan RH, Cahya NP. Potentially acute misoprostol toxicity during third-trimester pregnancy : a case report. 2023;12(1):606–8. DOI: http://dx.doi.org/10.15562/bmj.v12i1.3873.
  6. Stephenson ML, Wing DA. Misoprostol for induction of labor. Semin Perinatol. 2015;39(6):459–62. DOI: http://dx.doi.org/10.1053/j.semperi.2015.07.008
  7. Barnard S, Kim C, Park MH, Ngo TD. Doctors or mid-level providers for abortion. Cochrane Database Syst Rev. 2014;2014(7). DOI: https://doi.org/10.1002/14651858.cd011242.pub2.
  8. Bateson D, McNamee K, Harvey C. Medical abortion in primary care. Aust Prescr. 2021;44(6):187–92. DOI: https://doi.org/10.18773/austprescr.2021.050.
  9. Pourette D, Mattern C, Ratovoson R, Raharimalala P. Complications with use of misoprostol for abortion in Madagascar: between ease of access and lack of information. Contraception. 2018;97(2):116–21. DOI: https://doi.org/10.1016/j.contraception.2017.12.005.
  10. Machado LO, Taquette SR. The use of misoprostol in the termination of pregnancy: a review of studies carried out. Cienc e Saude Coletiva. 2022;27(8):3079–90. DOI: https://doi.org/10.1590/1413-81232022278.03102022.
  11. Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medical abortion in the late first trimester: a systematic review. Contraception. 2019;99(2):77–86. DOI: https://doi.org/10.1016/j.contraception.2018.11.002
  12. Jamali M, Bakhtiyari M, Arab F, Mirzamoradi M. Misoprostol complications in second-trimester termination of pregnancy among women with a history of more than one cesarean section. Obstet Gynecol Sci. 2020;63(3):323–9. DOI: https://doi.org/10.5468/ogs.2020.63.3.323.
  13. Nascimento MI Do, Cunha ADA, Oliveira SRDSM, Nunes GG, Alvarez FS, Villas Bôas EL. Misoprostol use under normal conditions for termination of pregnancies with intrauterine fetal death. Rev Assoc Med Bras. 2013;59(4):354–9. DOI: http://dx.doi.org/10.1016/j.ramb.2013.02.005
  14. Chahal H, Mumtaz Z. Abortion and fertility control in Pakistan: The role of misoprostol. J Fam Plan Reprod Heal Care. 2017;43(4):274–80. DOI: https://doi.org/10.1136/jfprhc-2015-101424.
  15. Kementrian Kesehatan. Undang-Undang Kesehatan. 2009;
  16. Upadhyay UD, Cartwright AF, Grossman D. Barriers to abortion care and incidence of attempted self-managed abortion among individuals searching Google for abortion care: A national prospective study. Contraception. 2022;106:49–56. DOI: https://doi.org/10.1016/j.contraception.2021.09.009
  17. Syamsun A, Kadriyan H, Lestari NPS, Lestarini IA, Rivarti AW, Bukhari A, et al. The role of the rapid molecular test (RMT) and the provision of a negative pressure mortuary room in reducing COVID-19 corpse handling protocol rejection: experiences with religious conservative groups. Egypt J Forensic Sci. 2022;12(1). DOI: https://doi.org/10.1186/s41935-022-00267-5
  18. Szpot P, Wachełko O, Zawadzki M. Forensic Toxicological Aspects of Misoprostol Use in Pharmacological Abortions. Molecules. 2022;27(19):1–14. DOI: https://doi.org/10.3390/molecules27196534.
  19. Drezett J, Bessa MMM, Pedroso D, Fernandes Silva AC, Gebrim LH, De Vasconcellos RM, et al. Misoprostol for induction of second trimester abortion in pregnancies resulting from sexual violence: Effectiveness analysis of a protocol applied in the Brazilian public health service. Reprod e Clim. 2014;29(3):105–11. DOI: http://dx.doi.org/10.1016/j.recli.2015.04.001
  20. WHO. Information sheet Safe and unsafe induced abortion Global and regional levels in 2008 , and trends during 1995 – 2008 Information sheet. Inf Sheet. 2008;1–8.
  21. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynecol Obstet. 2007;99(SUPPL. 2):160–7. DOI: https://doi.org/10.1016/j.ijgo.2007.09.004.
  22. Endler M, Lavelanet A, Cleeve A, Ganatra B, Gomperts R, Gemzell-Danielsson K. Telemedicine for medical abortion: a systematic review. BJOG An Int J Obstet Gynaecol. 2019;126(9):1094–102. DOI: https://doi.org/10.1111/1471-0528.15684.
  23. Yang YT, Kozhimannil KB. Medication Abortion Through Telemedicine. Obstet Gynecol. 2016;127(2):313–6. DOI: https://doi.org/10.1097/aog.0000000000001251.
  24. Aiken ARA, Lohr PA, Lord J, Ghosh N, Starling J. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG An Int J Obstet Gynaecol. 2021;128(9):1464–74. DOI: https://doi.org/10.1111/1471-0528.16668.

How to Cite

Syamsun, A. ., Sutjianto, J. ., Rahma, E. ., Masadah, R. ., Cangara, H. ., & Nelwan, B. J. . (2023). Effects of misoprostol as a drug to induce abortion in the second trimester: a forensic case report. Bali Medical Journal, 12(2), 2050–2054. https://doi.org/10.15562/bmj.v12i2.4509
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
21

Total
5

Share